Daiichi Sankyo Sees Strong Growth Despite OneāOff Costs
Daiichi Sankyo says its underlying business remains strong despite a oneātime expense and conservative earnings guidance that came in below market expectations. The Japanese drugmaker reported doubleādigit growth and rising revenue, supported by robust demand for its flagship cancer treatments. The company also outlined its mediumāterm outlook, highlighting antibodyādrug conjugates, research investment and the role of artificial intelligence, even as competition intensifies and currency moves remain a factor. Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo, spoke exclusively with Shery Ahn on Insight with Haslinda Amin about results, strategy and growth priorities. (Source: Bloomberg)
Send this story to anyone ā or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to Bloomberg Ā· Markets.
70% goes to the publisher Ā· 20% to whoever forwarded this to you Ā· 10% keeps Storyflo running. Pay with USDC (instant, on-chain) or card (Stripe ā Card, Link, Cash App, Apple Pay, Crypto, more).
Card path uses Stripe Checkout. USDC path settles on Base ā gas-free for you.